Publications by authors named "Jonathan J Keats"

46Publications

Glucocorticoid receptor expression in multiple myeloma patients is a predictor of survival.

Leuk Lymphoma 2020 Sep 13:1-5. Epub 2020 Sep 13.

City Hope National Medical Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1811860DOI Listing
September 2020

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.

Clin Cancer Res 2020 Sep 2;26(18):4832-4841. Epub 2020 Jul 2.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0951DOI Listing
September 2020

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Nat Commun 2019 04 23;10(1):1911. Epub 2019 Apr 23.

Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Rd. NE, Atlanta, GA, 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09555-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478743PMC
April 2019

Whole Exome Library Construction for Next Generation Sequencing.

Methods Mol Biol 2018 ;1706:163-174

Translational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, AZ, 85004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7471-9_9DOI Listing
October 2018

Whole Genome Library Construction for Next Generation Sequencing.

Methods Mol Biol 2018 ;1706:151-161

Translational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, AZ, 85004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7471-9_8DOI Listing
October 2018

Bringing RNA-seq closer to the clinic.

Nat Biotechnol 2014 Sep;32(9):884-5

Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.3017DOI Listing
September 2014

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Cancer Cell 2014 Jan;25(1):91-101

Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2013.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241387PMC
January 2014

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Blood 2010 Apr 6;115(17):3541-52. Epub 2010 Jan 6.

Genetics Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-09-243535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867265PMC
April 2010

Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.

J Clin Oncol 2009 Nov 5;27(33):e194-7. Epub 2009 Oct 5.

Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.0392DOI Listing
November 2009

Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.

Nat Immunol 2008 Dec 9;9(12):1364-70. Epub 2008 Nov 9.

Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, Cancer Center, University of California, San Diego, California 93093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ni.1678DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671996PMC
December 2008

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

Br J Haematol 2008 Feb 10;140(3):295-302. Epub 2007 Dec 10.

Department of Oncology, University of Alberta/Cross Cancer Institute, Edmonton, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2007.06913.xDOI Listing
February 2008

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

Leuk Lymphoma 2006 Nov;47(11):2289-300

Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190600822128DOI Listing
November 2006

Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.

Cancer Res 2005 Feb;65(3):850-60

Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2.

View Article

Download full-text PDF

Source
February 2005

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

Blood 2004 Aug 22;104(4):1151-8. Epub 2004 Apr 22.

Department of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-11-4079DOI Listing
August 2004

RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability.

Mol Biol Cell 2003 Jun 20;14(6):2262-76. Epub 2003 Mar 20.

Department of Oncology, University of Alberta/Cross Cancer Institute, Edmonton Alberta Canada T6G 1Z2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1091/mbc.e02-07-0377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC194876PMC
June 2003

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Blood 2003 Feb 3;101(4):1520-9. Epub 2002 Oct 3.

Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-06-1675DOI Listing
February 2003

Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.

Exp Hematol 2002 Mar;30(3):221-8

Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0301-472x(01)00788-3DOI Listing
March 2002